Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody as Monotherapy and in Combination With AGEN2034 (Balstilimab), an Anti-PD-1 Monoclonal Antibody, in Subjects With Advanced Cancer

NCT03860272 is registered in ClinicalTrials.gov with Agenus Inc. as lead sponsor.

NCT NCT03860272
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03860272 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody as Monotherapy and in Combination With AGEN2034 (Balstilimab), an Anti-PD-1 Monoclonal Antibody, in Subjects With Advanced Cancer
Lead sponsor
Agenus Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
March 20, 2019
Completion date
December 31, 2027
Enrollment
499 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, angiosarcoma, colorectal cancer without liver metastases, endometrial cancer, fibrolamellar carcinoma, non-small-cell lung cancer, ovarian cancer, prostate cancer